

## **MPAC meeting 12-14 March 2014**

### **Declaration of Interests**

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat.

Eleven members reported relevant interests, which are disclosed below. Of note, six MPAC members are involved with the RTS,S Phase 3 trial. However, since the update on the RTS,S vaccine from the JTEG contains no decision items and is for information only, it was concluded that all members could take part in full in all of the discussions at this meeting.

Any MPAC member with a personal, specific, or financially significant interest in the RTS,S vaccine will have no involvement in decision-making related to policy for RTS,S.

All the reported relevant interests are summarized below:

#### **Salim Abdulla**

Is director of the Ifakara Health Institute, which receives research funding from MVI and MMV. This interest was assessed as non-personal, specific and financially significant\*.

#### **Pedro Alonso**

Is an author on the RTS,S Phase 3 trial manuscript. This interest was assessed as non-personal, specific and financially significant\*.

#### **Fred Binka**

Receives research support from the Bill & Melinda Gates Foundation. This interest was assessed as non-personal, non-specific and financially significant\*.

#### **Brian Greenwood**

Receives research funding from the Malaria Vaccine Initiative for the RTS,S vaccine trial. This interest was assessed as non-personal, specific, and financially significant\*.

#### **Rose Leke**

Receives funding from Pfizer as a consultant. This interest was assessed as personal, non-specific and not financially significant\*. She also receives research funding from the National Institute of Allergy and Infectious Diseases (NIAID), USA. This interest was assessed as non-personal, non-specific and financially significant\*.

#### **Kevin Marsh**

Is on advisory boards for USAID and SUDA, and is a PI on the Phase 3 RTS,S study and a collaborator on a Phase 2 malaria vaccine study. This interest was assessed as non-personal, specific, and non-financially significant\*.

#### **Sylvia Meek**

Is technical director of the Malaria Consortium which receives research funding from the Bill & Melinda Gates Foundation, DfID, AusAID, and CDC. This interest was assessed as being non-personal, non-specific, and financially significant\*.

**Allan Schapira**

Received consultancy fees from GHTech, the Bill & Melinda Gates Foundation, World Bank, UNDP, and the Swiss Tropical and Public Health Institute. This interest was assessed as being personal, non-specific, and financially significant\*.

**Laurence Slutsker**

Receives research support from MVI. This interest was assessed as personal, specific and not financially significant\*.

**Marcel Tanner**

Directs the Swiss Tropical and Public Health Institute which receives research funding from Novartis Institute for Tropical Diseases, SNF, MMV, Wellcome Trust, Malaria Vaccine Initiative and the Bill & Melinda Gates Foundation. This interest was assessed to be non-personal, specific, and financial significant\*.

**Nick White**

Receives research funding from MMV, Novartis, Holley-Cotec and GSK. This interest was assessed to be non-personal, non-specific, and financially significant\*.

---

\* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a "significant shareholding".

Last updated: 11 March 2014